MAPT and Alzheimer disease: Initial studies of pathological (e.g. beta-amyloid and tau measurements) and neuronal loss (e.g. hippocampal volumetric imaging) biomarkers has also suggested there may be sex differences in the evolution of AD pathophysiology1,13,20–23, reviewed in1 and6.